Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AQUABOUNTY TECHNOLOGIES INCAQB · Entity 8187 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AQUABOUNTY TECHNOLOGIES INC
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,000 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 55,555 · Balance 65,000 F1: Restricted Share Unit award granted on 06/14/2023, pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan that vests in two tranches with 1/2 vesting on May 25, 2024 and 1/2 vesting on May 25, 2025. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2033-05-25 | Direct | 2,500 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 2,500 · Balance 2,500 F2: Stock Option award granted on 06/14/2023, pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan that vests daily over the period of May 25, 2023 through May 25, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Share Unit award granted on 06/14/2023, pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan that vests in two tranches with 1/2 vesting on May 25, 2024 and 1/2 vesting on May 25, 2025.
F2: Stock Option award granted on 06/14/2023, pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan that vests daily over the period of May 25, 2023 through May 25, 2024.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fibrocell Science, Inc.
Report date December 13, 2019 · Filed December 13, 2019
Section 16 reporting ended · disclosed 2019-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 1
1 source rowRow 1 · 2019-12-13 · Disposition to issuer · Disposed 667 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.50 · Expires 2023-02-21 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-13 · Disposition to issuer · Disposed 534 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.35 · Expires 2023-07-19 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-13 · Disposition to issuer · Disposed 1,600 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $81.60 · Expires 2025-06-24 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-13 · Disposition to issuer · Disposed 2,400 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.55 · Expires 2026-06-22 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-13 · Disposition to issuer · Disposed 2,400 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.55 · Expires 2027-06-22 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-13 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-13 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.94 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-12-13 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $62.10 · Expires 2024-06-20 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-13 · Disposition to issuer · Disposed 1,200 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.
Tilray Brands, Inc.
Report date April 30, 2021 · Filed May 06, 2021
Section 16 reporting ended · disclosed 2021-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class 2 Common StockSEC Table I · non-derivative | Direct | 58,143 |
Reported balance
After 2021-04-30 transaction · row 1
1 source rowRow 1 · 2021-04-30 · Exercise / conversion · Acquired 37,310 · Balance 58,143 F1: Restricted Stock Units ("RSUs") convert into shares of Class 2 Common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-30 · Exercise / conversion · Disposed 37,310 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into shares of Class 2 Common stock on a one-for-one basis. F2: RSUs granted to the Reporting Person were accelerated and became fully vested on April 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into shares of Class 2 Common stock on a one-for-one basis.
F2: RSUs granted to the Reporting Person were accelerated and became fully vested on April 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2023 Filed Jun 16, 2023 08:39 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001209191-23-037646 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-05-25 F2 · derivative.exercise_date: Stock Option award granted on 06/14/2023, pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan that vests daily over the period of May 25, 2023 through May 25, 2024. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 08:39 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantCommon Stock | 55,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037646 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · shares: Restricted Share Unit award granted on 06/14/2023, pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan that vests in two tranches with 1/2 vesting on May 25, 2024 and 1/2 vesting on May 25, 2025. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 15:55 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | PurchaseCommon Stock | 10,000 | $0.78 | $7,783.00 |
DisclosureSEC source: 0001209191-22-062318 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · security: Purchase of 10,000 shares at $.7783 12/20/2022 Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 11:15 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001209191-22-019079 · doc4.xml · derivative · entry 9 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2032-03-14 F11 · derivative.exercise_date: Options to purchase common stock were granted on 3/14/2022 pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan and fully vest one year after the date of grant. Read SEC document |
| April 30, 2021 Filed May 6, 2021 01:24 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 37,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-016041 · form4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class 2 Common Stock · 37,310 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into shares of Class 2 Common stock on a one-for-one basis. F2 · derivative.exercise_date: RSUs granted to the Reporting Person were accelerated and became fully vested on April 30, 2021. F2 · derivative.expiration_date: RSUs granted to the Reporting Person were accelerated and became fully vested on April 30, 2021. Read SEC document |
| April 30, 2021 Filed May 6, 2021 01:24 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 37,310 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-016041 · form4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into shares of Class 2 Common stock on a one-for-one basis. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 18:17 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-21-019914 · doc4.xml · derivative · entry 8 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-03-10 F10 · derivative.exercise_date: Options to purchase common stock were granted on 3/10/2021 pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan and fully vest one year after the date of grant. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:02 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017321 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,938 Underlying: Class 2 Common Stock · 2,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class 2 Common Stock. F3 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of RSUs on each quarterly anniversary of the Vesting Date thereafter for so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:02 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017321 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 23:30 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | SaleClass 2 Common Stock | 2,200 | $10.00 | $22,000.00 |
DisclosureSEC source: 0001209191-20-064499 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,646 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:59 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061589 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Class 2 Common Stock · 2,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class 2 Common Stock. F3 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of the RSUs on each quarterly anniversary of the Vesting Date for so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:59 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-061589 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| November 06, 2020 Filed Nov 11, 2020 00:11 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | SaleClass 2 Common Stock | 4,400 | $10.05 | $44,233.20 |
DisclosureSEC source: 0001209191-20-057774 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,658 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote 2 to this Form 4. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:51 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049504 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,313 Underlying: Class 2 Common Stock · 2,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Class 2 Common Stock. F3 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of the RSUs on each quarterly anniversary of the Vesting Date for so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:51 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-049504 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| June 05, 2020 Filed Jun 10, 2020 00:13 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | GrantRestricted Stock Units · Derivative | 26,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035420 · doc4.xml · derivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,372 Underlying: Class 2 Common Stock · 26,372 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class 2 Common Stock. F2 · derivative.exercise_date: The RSUs shall vest in full upon the earlier of (1) the date of the 2021 Annual Meeting of Stockholders of the Issuer and (2) the one-year anniversary of May 28, 2020 so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), through such vesting date. F2 · derivative.expiration_date: The RSUs shall vest in full upon the earlier of (1) the date of the 2021 Annual Meeting of Stockholders of the Issuer and (2) the one-year anniversary of May 28, 2020 so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), through such vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 23:53 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034315 · doc4.xml · derivative · entry 4 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Class 2 Common Stock · 2,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. F3 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of the RSUs on each quarterly anniversary of the Vesting Date for so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 23:53 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034315 · doc4.xml · nonDerivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| May 28, 2020 Filed Jun 3, 2020 23:53 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 7,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034315 · doc4.xml · derivative · entry 3 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class 2 Common Stock · 7,371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. F2 · derivative.expiration_date: The RSUs shall vest in full upon the earlier of (1) the date of the 2020 Annual Meeting of Stockholders of the Issuer (which occurred on May 28, 2020), and (2) the one-year anniversary of June 1, 2019 so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), through such vesting date. Read SEC document |
| May 28, 2020 Filed Jun 3, 2020 23:53 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 7,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034315 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 17:20 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001603978-20-000064 · wf-form4_158439363685670.xml · derivative · entry 7 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2030-03-12 F9 · derivative.exercise_date: Options to purchase common stock were granted on 3/12/2020 pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan and fully vest one year after the date of grant. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:46 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015737 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,688 Underlying: Class 2 Common Stock · 2,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. F2 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of RSUs on each quarterly anniversary of the Vesting Date thereafter for so long as the Reporting Person remains in Continuous Service (as defined in the Company's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:46 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-015737 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,000 | Not disclosed Strike: $1.94 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 9 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2029-06-12 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,000 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 8 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2028-06-19 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,000 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 7 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-06-22 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,400 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 6 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2026-06-22 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,400 | Not disclosed Strike: $81.60 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 5 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2025-06-24 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOptions to purchase common stock · Derivative | 1,200 | Not disclosed Strike: $62.10 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 4 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires 2024-06-20 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,600 | Not disclosed Strike: $82.35 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 3 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,600 shares Expires 2023-07-19 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 534 | Not disclosed Strike: $52.50 | Not disclosed |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 534 shares Expires 2023-02-21 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:19 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerCommon Stock | 667 | $3.00 | $2,001.00 |
DisclosureSEC source: 0001628280-19-015083 · wf-form4_157627193610644.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00. Read SEC document |
| December 01, 2019 Filed Dec 4, 2019 00:18 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Units · Derivative | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058875 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Class 2 Common Stock · 2,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. F2 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of RSUs on each quarterly anniversary of the Vesting Date thereafter for so long as the Reporting Person remains in Continuous Service (as defined in the Company's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| December 01, 2019 Filed Dec 4, 2019 00:18 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-058875 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| September 01, 2019 Filed Sep 3, 2019 21:21 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Unit · Derivative | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-048008 · doc4.xml · derivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,063 Underlying: Clas 2 Common Stock · 2,187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. F2 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of RSUs on each quarterly anniversary of the Vesting Date thereafter for so long as the Reporting Person remains in Continuous Service (as defined in the Company's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| September 01, 2019 Filed Sep 3, 2019 21:21 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 2,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-048008 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of Class 2 Common Stock. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 23:09 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | SaleClass 2 Common Stock | 4,000 | $50.01 | $200,024.40 |
DisclosureSEC source: 0001209191-19-038841 · doc4.xml · nonDerivative · entry 2 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote 3 to this Form 4. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:31 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | GrantOption to Purchase Common Stock · Derivative | 12,000 | Not disclosed Strike: $1.94 | Not disclosed |
DisclosureSEC source: 0001628280-19-008006 · wf-form4_156054428901263.xml · derivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-12 F2 · price: The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors. F1 · derivative.exercise_date: 50% of the shares vest and become exercisable on the earlier of (x) June 12, 2020 and (y) the date of the Company's 2020 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 12, 2021 and (y) the date of the Company's 2021 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:43 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | GrantRestricted Stock Units · Derivative | 7,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036146 · doc4.xml · derivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,371 Underlying: Class 2 Common Stock · 7,371 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class 2 Common Stock. F2 · derivative.exercise_date: The RSUs shall vest in full upon the earlier of (1) the one-year anniversary of June 1, 2019 (the "Vesting Date") and (2) the date of the 2020 Annual Meeting of Stockholders of the Issuer, so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), through such Vesting Date. F2 · derivative.expiration_date: The RSUs shall vest in full upon the earlier of (1) the one-year anniversary of June 1, 2019 (the "Vesting Date") and (2) the date of the 2020 Annual Meeting of Stockholders of the Issuer, so long as the Reporting Person remains in Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan), through such Vesting Date. Read SEC document |
| June 01, 2019 Filed Jun 24, 2019 23:09 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionRestricted Stock Unit · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038841 · doc4.xml · derivative · entry 3 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Class 2 Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Class 2 Common Stock. F4 · derivative.expiration_date: The RSUs shall vest at the rate of 25% of the RSUs on the twelve (12) month anniversary of June 1, 2018 (the "Vesting Date"), and the remaining RSUs will vest quarterly thereafter at the rate of 6.25% of the total number of RSUs on each quarterly anniversary of the Vesting Date thereafter for so long as the Reporting Person remains in Continuous Service (as defined in the Company's 2018 Equity Incentive Plan), such that the total number of RSUs shall be fully vested on the four-year anniversary of the Vesting Date. Read SEC document |
| June 01, 2019 Filed Jun 24, 2019 23:09 UTC | Tilray Brands, Inc. TLRY · Entity 5319 | Exercise / conversionClass 2 Common Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-038841 · doc4.xml · nonDerivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Class 2 Common Stock. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 11:42 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001603978-19-000009 · wf-form4_155197692681576.xml · derivative · entry 6 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-03-05 F8 · derivative.exercise_date: Options to purchase common stock were granted on 3/5/2019 pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan and fully vest one year from the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 16:11 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | GrantOption to Purchase Common Stock · Derivative | 6,000 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001628280-18-008178 · wf-form4_152961185045366.xml · derivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-19 F2 · price: The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors. F1 · derivative.exercise_date: 50% of the shares vest and become exercisable on the earlier of (x) June 19, 2019 and (y) the date of the Company's 2019 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 19, 2020 and (y) the date of the Company's 2020 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:20 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001603978-18-000017 · wf-form4_151993917151309.xml · derivative · entry 5 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2028-02-27 F7 · derivative.exercise_date: Options to purchase common stock were granted on 2/27/2018 pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan and fully vest one year after the date of grant. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 19:34 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | GrantOption to Purchase Common Stock · Derivative | 30,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001628280-17-006737 · wf-form4_149852006507013.xml · derivative · entry 1 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-22 F2 · price: The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors. F1 · derivative.exercise_date: 50% of the shares vest and become exercisable on the earlier of (x) June 22, 2018 and (y) the date of the Company's 2018 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 22, 2019 and (y) the date of the Company's 2019 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 17:12 UTC | AQUABOUNTY TECHNOLOGIES INC AQB · Entity 8187 | GrantOptions to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0001603978-17-000029 · wf-form4_149306831714190.xml · derivative · entry 4 St.Clare Christine · CIK 0001570393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2027-04-21 F6 · derivative.exercise_date: Options to purchase common stock were granted on 4/21/2017 pursuant to the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan. Subject to continued service, vesting shall occur over three years, ending February 27, 2020, with the first year's vesting prorated between April 22, 2017, and February 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.